Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul;74(10):1153-63.
doi: 10.1007/s40265-014-0252-2.

Vorapaxar: first global approval

Raewyn M Poole  1 , Shelley Elkinson
Affiliations
Review

Vorapaxar: first global approval

Raewyn M Poole et al. Drugs. 2014 Jul.

Abstract

Vorapaxar [Zontivity(®) (US)], an orally active protease-activated receptor-1 (PAR-1) receptor antagonist, has been developed by Merck & Co for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). Vorapaxar has received its first global approval for this indication in the US. This article summarizes the milestones in the development of vorapaxar leading to this first approval for the reduction of thrombotic cardiovascular events in patients with a prior MI or PAD.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Vasc Health Risk Manag. 2014 Apr 03;10:177-88 - PubMed
    1. Thromb Haemost. 2014 May 5;111(5):883-91 - PubMed
    1. Stroke. 2013 Mar;44(3):691-8 - PubMed
    1. Clin Pharmacol Drug Dev. 2013 Jan;2(1):90-8 - PubMed
    1. Circulation. 2011 May 10;123(18):e426-579 - PubMed

MeSH terms

LinkOut - more resources